• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals

  • Print
  • Share
  • E-mail
Generic Name:  maribavir
Trade Name:  Livtencity
Date Designated:  06/07/2011
Orphan Designation:  Treatment of clinically significant cytomegalovirus viremia and disease in at-risk patients.
Orphan Designation Status:  Designated/Approved
Marketing Approval Date:  11/23/2021 
Approved Labeled Indication:  Treatment of adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant cytomegalovirus (CMV) infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet
Exclusivity End Date:     
Exclusivity Protected Indication* :  
Takeda Pharmaceuticals USA, Inc.
650 East Kendall Street
Cambridge, Massachusetts 02142
United States

The sponsor address listed is the last reported by the sponsor to OOPD.
*Exclusivity Protected Indications are shown for approvals from Jan. 1, 2013, to the present.